Eurobio Scientific Presented Breast Cancer Research at ESMO 2022

Eurobio Scientific participated in an industry satellite symposium held in conjunction with the European Society for Medical Oncology (ESMO) congress in September 2022.

The event showcased new data on the EndoPredict test's utility in guiding treatment decisions for early-stage, hormone-sensitive, HER2-negative breast cancer in postmenopausal patients. The aim is to help clinicians make more precise therapeutic choices and avoid unnecessary chemotherapy.

During the symposium, findings presented by researcher Anastasia Constantinidou emphasized the significance of the EndoPredict test in tailoring treatment pathways. The test provides a genetic signature that aids in predicting recurrence risk and selecting the optimal course of action.

Eurobio Scientific, specializing in diagnostics and medical biology, acts as a distributor for various international companies in France. The company focuses on areas including cancer diagnostics and other specialties, supporting healthcare professionals with advanced technologies.